ZOLPIDEM TARTRATE - Generic Drug Details
✉ Email this page to a colleague
What are the generic drug sources for zolpidem tartrate and what is the scope of patent protection?
Zolpidem tartrate
is the generic ingredient in seven branded drugs marketed by Almatica, Aytu, Sanofi Aventis Us, Actavis Elizabeth, Actavis Labs Fl Inc, Apotex, Breckenridge, Endo Operations, Lupin Ltd, Sandoz, Sun Pharm, Synthon Pharms, Biovail Labs Intl, Acme Labs, Apotex Inc, Aurobindo Pharma, Chartwell Molecular, Dr Reddys Labs Ltd, Hikma, Invagen Pharms, Mylan Pharms Inc, Rising, Strides Pharma, Sun Pharm Inds Inc, Sun Pharm Inds Ltd, Sun Pharm Industries, Teva, Torrent Pharms, Watson Labs, Wockhardt, Yung Shin Pharm, Mylan Speciality Lp, Purdue Pharma, Dr Reddys, Norvium Bioscience, and Novel Labs Inc, and is included in forty-two NDAs. There are seven patents protecting this compound and four Paragraph IV challenges. Additional information is available in the individual branded drug profile pages.Zolpidem tartrate has one hundred and forty-one patent family members in twenty-three countries.
There are thirty-two drug master file entries for zolpidem tartrate. Forty-six suppliers are listed for this compound. There are two tentative approvals for this compound.
Summary for ZOLPIDEM TARTRATE
International Patents: | 141 |
US Patents: | 7 |
Tradenames: | 7 |
Applicants: | 36 |
NDAs: | 42 |
Drug Master File Entries: | 32 |
Finished Product Suppliers / Packagers: | 46 |
Raw Ingredient (Bulk) Api Vendors: | 18 |
Clinical Trials: | 24 |
Patent Applications: | 1,068 |
Drug Prices: | Drug price trends for ZOLPIDEM TARTRATE |
Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for ZOLPIDEM TARTRATE |
What excipients (inactive ingredients) are in ZOLPIDEM TARTRATE? | ZOLPIDEM TARTRATE excipients list |
DailyMed Link: | ZOLPIDEM TARTRATE at DailyMed |
Recent Clinical Trials for ZOLPIDEM TARTRATE
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
National Institute on Aging (NIA) | Phase 4 |
University of Pennsylvania | Phase 4 |
National Institutes of Health (NIH) | Phase 4 |
Generic filers with tentative approvals for ZOLPIDEM TARTRATE
Applicant | Application No. | Strength | Dosage Form |
⤷ Sign Up | ⤷ Sign Up | 10MG | TABLET;ORAL |
⤷ Sign Up | ⤷ Sign Up | 5MG | TABLET;ORAL |
⤷ Sign Up | ⤷ Sign Up | 5MG | TABLET;ORAL |
The 'tentative' approval signifies that the product meets all FDA standards for marketing, and, but for the patents / regulatory protections, it would approved.
Pharmacology for ZOLPIDEM TARTRATE
Drug Class | gamma-Aminobutyric Acid A Receptor Positive Modulator gamma-Aminobutyric Acid-ergic Agonist |
Mechanism of Action | GABA A Receptor Positive Modulators GABA A Agonists |
Physiological Effect | Central Nervous System Depression |
Anatomical Therapeutic Chemical (ATC) Classes for ZOLPIDEM TARTRATE
Paragraph IV (Patent) Challenges for ZOLPIDEM TARTRATE
Tradename | Dosage | Ingredient | Strength | NDA | ANDAs Submitted | Submissiondate |
---|---|---|---|---|---|---|
INTERMEZZO | Sublingual Tablets | zolpidem tartrate | 1.75 mg and 3.5 mg | 022328 | 1 | 2012-04-10 |
EDLUAR | Sublingual Tablets | zolpidem tartrate | 5 mg and 10 mg | 021997 | 1 | 2010-04-29 |
AMBIEN CR | Extended-release Tablets | zolpidem tartrate | 6.25 mg | 021774 | 1 | 2006-02-24 |
AMBIEN CR | Extended-release Tablets | zolpidem tartrate | 12.5 mg | 021774 | 1 | 2006-01-19 |
US Patents and Regulatory Information for ZOLPIDEM TARTRATE
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Apotex | ZOLPIDEM TARTRATE | zolpidem tartrate | TABLET, EXTENDED RELEASE;ORAL | 200266-002 | Sep 10, 2013 | AB | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
Purdue Pharma | INTERMEZZO | zolpidem tartrate | TABLET;SUBLINGUAL | 022328-001 | Nov 23, 2011 | DISCN | Yes | No | ⤷ Sign Up | ⤷ Sign Up | Y | ⤷ Sign Up | |||
Rising | ZOLPIDEM TARTRATE | zolpidem tartrate | TABLET;ORAL | 076578-001 | Apr 23, 2007 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
Novel Labs Inc | ZOLPIDEM TARTRATE | zolpidem tartrate | TABLET;SUBLINGUAL | 204299-002 | Jun 3, 2015 | AB | RX | No | Yes | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
Mylan Pharms Inc | ZOLPIDEM TARTRATE | zolpidem tartrate | TABLET;ORAL | 078016-002 | Apr 23, 2007 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
Sun Pharm Inds Ltd | ZOLPIDEM TARTRATE | zolpidem tartrate | TABLET;ORAL | 078055-002 | Apr 23, 2007 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
Apotex | ZOLPIDEM TARTRATE | zolpidem tartrate | TABLET, EXTENDED RELEASE;ORAL | 200266-001 | Sep 10, 2013 | AB | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for ZOLPIDEM TARTRATE
International Patents for ZOLPIDEM TARTRATE
Country | Patent Number | Title | Estimated Expiration |
---|---|---|---|
New Zealand | 561128 | Buccal, polar and non-polar spray or capsule containing drugs for treating disorders of the gastrointestinal tract or urinary tract | ⤷ Sign Up |
Canada | 2609330 | COMPOSITIONS SOLIDES ET TECHNIQUES DE TRAITEMENT D'INSOMNIE SURVENANT AU MILIEU DE LA NUIT (SOLID COMPOSITIONS AND METHODS FOR TREATING MIDDLE-OF-THE NIGHT INSOMNIA) | ⤷ Sign Up |
European Patent Office | 1807156 | NOUVELLES PREPARATIONS PHARMACEUTIQUES UTILES DANS LE TRAITEMENT DE L'INSOMNIE (NEW PHARMACEUTICAL FORMULATIONS USEFUL IN THE TREATMENT OF INSOMNIA) | ⤷ Sign Up |
Poland | 1807156 | ⤷ Sign Up | |
Canada | 2582008 | SPRAY NON POLAIRE, POLAIRE ET BUCCAL CONTENANT DU SUMATRIPTAN (BUCCAL, POLAR AND NON-POLAR SPRAY CONTAINING SUMATRIPTAN) | ⤷ Sign Up |
Australia | 2006249761 | Solid compositions and methods for treating middle-of-the night insomnia | ⤷ Sign Up |
World Intellectual Property Organization (WIPO) | 2004019909 | ⤷ Sign Up | |
>Country | >Patent Number | >Title | >Estimated Expiration |
Supplementary Protection Certificates for ZOLPIDEM TARTRATE
Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
---|---|---|---|---|
2236132 | CA 2015 00004 | Denmark | ⤷ Sign Up | PRODUCT NAME: ZOLPIDEM OG FARMACEUTISK ACCEPTABLE SALTE HERAF, HERUNDER ZOLPIDEMTARTRAT; NAT. REG. NO/DATE: 47607 OG 47608 20120719; FIRST REG. NO/DATE: (B BE424286 OG BE424295 20120718 |
2236132 | 92636 | Luxembourg | ⤷ Sign Up | PRODUCT NAME: ZOLPIDEM ET SES SELS PHARMACEUTIQUEMENT ACCEPTABLES |
2236132 | 122015000006 | Germany | ⤷ Sign Up | PRODUCT NAME: ZOLPIDEM UND PHARMAZEUTISCH VERTRAEGLICHE SALZE DAVON; NAT. REGISTRATION NO/DATE: 83439.00.00 83440.00.00 20120725 FIRST REGISTRATION: BELGIEN BE424286 BE424295 20120718 |
2236132 | C300714 | Netherlands | ⤷ Sign Up | PRODUCT NAME: ZOLPIDEM EN FARMACEUTISCH AANVAARDBARE ZOUTEN DAARVAN; NAT. REGISTRATION NO/DATE: RVG 108438 - 439 20130624; FIRST REGISTRATION: BE424286BE424295 2012180718 |
2236132 | 300714 | Netherlands | ⤷ Sign Up | PRODUCT NAME: ZOLPIDEM EN FARMACEUTISCH AANVAARDBARE ZOUTEN DAARVAN; NATIONAL REGISTRATION NO/DATE: RVG 108438 - 439 20160624; REGISTRATION NO/DATE: BE424286 20120718 BE424295 20120718 |
>Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.